Welcome to our dedicated page for Tango Therapeutics news (Ticker: TNGX), a resource for investors and traders seeking the latest updates and insights on Tango Therapeutics stock.
Tango Therapeutics, Inc. reports developments as a clinical-stage biotechnology company focused on precision oncology. The company uses the genetic principle of synthetic lethality to discover and develop cancer therapies, with news centered on its PRMT5 inhibitor program, including vopimetostat, and related oncology combination research.
Recurring updates also cover financial results and business highlights, clinical supply and collaboration activity, investor-conference participation, board and executive appointments, and equity compensation actions under the company’s 2023 Inducement Plan pursuant to Nasdaq Listing Rule 5635(c)(4).
Tango Therapeutics (NASDAQ:TNGX) reported second quarter 2026 results and advanced its PRMT5 program. Initial Phase 1/2 data showed vopimetostat plus Revolution Medicines’ RAS(ON) inhibitor daraxonrasib achieved a 92% objective response rate and 90% six‑month progression-free survival in MTAP-deleted, RAS-mutant pancreatic cancer, with a generally well-tolerated safety profile. Tango is engaging regulators and its collaborator to define a registrational path and plans a Phase 3 trial design in 2H 2026.
The company held $1.0 billion in cash, cash equivalents and marketable securities as of June 30, 2026. Q2 2026 collaboration revenue was $0 versus $3.2 million a year earlier. Research and development expenses were $37.2 million and general and administrative expenses were $22.6 million, leading to a net loss of $55.3 million ($0.37/share) versus $38.9 million ($0.35/share) in Q2 2025. Key hires include Chief Commercialization Officer Fatma Ocak and Board Chairman Robert Azelby.
Tango Therapeutics (NASDAQ: TNGX)/b) announced that Dr. Barbara Weber, Executive Chairman of the Board of Directors, will be stepping down in connection with other pursuits. The company describes itself as a clinical-stage biotechnology company focused on precision cancer medicines.Dr. Weber stated she is proud of Tango’s achievements and believes the company is well positioned to continue building on them. According to Tango Therapeutics, President Dr. Malte Peters expressed profound gratitude for Dr. Weber’s vision, leadership, passion for the organization and its employees, and her commitment to its groundbreaking oncology work.
Tango Therapeutics (NASDAQ:TNGX) appointed biopharma executive Robert Azelby to its Board of Directors. He brings more than 30 years of leadership in oncology commercialization, corporate strategy and governance. The appointment comes as Tango advances vopimetostat, an investigational PRMT5 inhibitor, toward potential late-stage development for MTAP-deleted pancreatic cancers.
Tango Therapeutics (Nasdaq:TNGX) priced an upsized underwritten public offering of 18,166,667 common shares and pre-funded warrants to purchase up to 1,833,395 shares at $30.00 per share and $29.999 per warrant.
Gross proceeds are expected to be about $600 million, with a 30-day option for underwriters to buy up to 3,000,009 additional shares. Closing is expected around June 11, 2026.
Tango Therapeutics (Nasdaq:TNGX) launched an underwritten public offering of $500 million in common stock. All shares are offered by the company, with a planned 30-day option for underwriters to purchase up to an additional $75 million in shares, subject to market conditions.
Tango Therapeutics (NASDAQ:TNGX) reported initial Phase 1/2 data for vopimetostat combinations in MTAP-deleted, RAS-mutant cancers. In second/third-line pancreatic ductal adenocarcinoma, vopimetostat plus daraxonrasib showed 92% ORR, 90% 6‑month PFS and 100% DCR, with 100% ORR in a small NSCLC cohort.
The vopimetostat plus zoldonrasib regimen in pancreatic cancer achieved 52% ORR, 74% 6‑month PFS and 96% DCR. Both combinations were generally well tolerated without related Grade 4/5 events. Tango plans a front-line Phase 3 pancreatic cancer trial and multiple additional data readouts in 2H 2026.
Tango Therapeutics (NASDAQ:TNGX) granted equity awards under its 2023 Inducement Plan, effective June 1, 2026, pursuant to Nasdaq Rule 5635(c)(4).
A new employee received a non-qualified option for 170,000 shares at an exercise price of $23.10 and 40,000 RSUs, with multi‑year vesting tied to continued employment.
Tango Therapeutics (NASDAQ:TNGX) reported first quarter 2026 results and pipeline progress. Cash, cash equivalents and marketable securities totaled $379.8 million as of March 31, 2026, expected to fund operations into 2028.
Net loss was $45.5 million ($0.32/share). Vopimetostat combination trials, TNG456 and multiple 2026 data readouts are key upcoming milestones, alongside new senior leadership hires and board changes.
Tango Therapeutics (NASDAQ: TNGX) announced inducement equity awards effective May 1, 2026 under its 2023 Inducement Plan.
The Compensation Committee granted Mr. Matthew Gall a non‑qualified option for 240,000 shares and 40,000 RSUs, and a new employee an option for 199,650 shares and 33,250 RSUs, at an exercise price of $20.98 per share. Options have a 10‑year term; option vesting: 25% at year one then monthly over three years; RSUs vest in three approximately equal annual installments in May 2027–2029. Awards are subject to the 2023 Inducement Plan and award agreements.
Tango Therapeutics (NASDAQ: TNGX) announced leadership appointments to advance vopimetostat, a selective PRMT5 inhibitor, toward potential regulatory approval in pancreatic cancer. Appointments effective April 15 include Matthew Gall as CFO and Janice Kapty, PhD as SVP, with Yen-Ching Chua joining as Chief Development Operations Officer effective June 1.
The hires add finance, global clinical operations, and portfolio strategy expertise to support late-stage development and anticipated initial combination trial data with Revolution Medicines’ RAS(ON) inhibitors this year.